Sulfisomidine - Misplaced Pages

Chemical compound Pharmaceutical compound

Sulfisomidine
Clinical data


Routes of administration	Oral
ATC code	J01EB01 (WHO)
Pharmacokinetic data
Metabolism	Minor acetylation
Excretion	Renal, 85%
Identifiers
IUPAC name 4-amino-N-(2,6-dimethylpyrimidin-4-yl) benzenesulfonamide
CAS Number	515-64-0
PubChem CID	5343
ChemSpider	5150
UNII	W03L3ODK6E
KEGG	D01526
ChEBI	CHEBI:32166
ChEMBL	ChEMBL485696
CompTox Dashboard (EPA)	DTXSID1046390
ECHA InfoCard	100.007.460
Chemical and physical data
Formula	C₁₂H₁₄N₄O₂S
Molar mass	278.33 g·mol
3D model (JSmol)	Interactive image
SMILES O=S(=O)(Nc1nc(nc(c1)C)C)c2ccc(N)cc2
InChI InChI=1S/C12H14N4O2S/c1-8-7-12(15-9(2)14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16) Key:YZMCKZRAOLZXAZ-UHFFFAOYSA-N
(what is this?) (verify)

Sulfisomidine (INN), also known as sulphasomidine (BAN until 2003), sulfamethin and sulfaisodimidine, is a sulfonamide antibacterial. It is closely related to sulfadimidine.

References

"Changing substance names from BANs to rINNs" (PDF). Archived from the original on 2005-08-27.{{cite web}}: CS1 maint: bot: original URL status unknown (link) (34.5 KiB). United Kingdom Medicines and Healthcare products Regulatory Agency (December 12, 2003). Retrieved on 2007-08-26 through Archive.org.

External links

Melander A, Bitzén PO, Olsson S (1982). "Therapeutic equivalence of sulfaisodimidine 2 g twice daily and 1 g four times daily in lower urinary tract infections". Acta Medica Scandinavica. 211 (5): 361–4. doi:10.1111/j.0954-6820.1982.tb01962.x. PMID 7051761.

Antibacterials that inhibit nucleic acid (J01E, J01M)

Antifolates
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)

DHFR inhibitor

2,4-Diaminopyrimidine

Sulfonamides
(DHPS inhibitor)

Short-acting	Sulfaisodimidine Sulfamethizole Sulfadimidine (Sulfamethazine, Sulfadimerazine, Sulfadimezine) Sulfapyridine (Sulfasalazine) Sulfafurazole (Acetyl sulfisoxazole) Sulfanilamide Prontosil Sulfathiazole (Phthalylsulfathiazole, Succinylsulfathiazole) Sulfathiourea
Intermediate-acting	Sulfamethoxazole Sulfadiazine Sulfamoxole
Long-acting	Sulfadimethoxine Sulfadoxine Sulfalene Sulfametomidine Sulfametoxydiazine Sulfamethoxypyridazine Sulfaperin Sulfamerazine Sulfaphenazole Sulfamazone
Other/ungrouped	Mafenide Sulfacetamide Sulfaclozine Sulfadicramide Sulfaguanidine Sulfametrole Sulfanitran

Combinations

Other DHPS inhibitors

Quinolones
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)

1st generation

Fluoroquinolones

2nd generation	Ciprofloxacin Ofloxacin Enoxacin Fleroxacin Lomefloxacin Nadifloxacin/Levonadifloxacin/Alalevonadifloxacin Norfloxacin Pefloxacin Rufloxacin
3rd generation	Levofloxacin Balofloxacin Grepafloxacin Pazufloxacin Sparfloxacin Temafloxacin Tosufloxacin
4th generation	Besifloxacin Delafloxacin Gatifloxacin Finafloxacin Gemifloxacin Moxifloxacin Clinafloxacin Garenoxacin Prulifloxacin Sitafloxacin Trovafloxacin/Alatrofloxacin
Veterinary	Danofloxacin Difloxacin Enrofloxacin Ibafloxacin Marbofloxacin Orbifloxacin Pradofloxacin Sarafloxacin

Newer non-fluorinated

Related (DG)

Aminocoumarins: Novobiocin

Anaerobic DNA
inhibitors

Nitroimidazole derivatives	Secnidazole

RNA synthesis

Rifamycins/ RNA polymerase	Rifampicin Rifabutin Rifapentine Rifaximin Rifalazil
Lipiarmycins	Fidaxomicin

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This systemic antibiotic-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: